Who
Bihua Chen
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, BlossomHill Therapeutics; CEO and Chairperson, BridgeBio Oncology Therapeutics; Chairperson and CEO, Helix Acquisition Corp. III; 10% owner, Corbus Pharmaceuticals Holdings; Director and 10% owner, Biomea Fusion; Other, Aardvark Therapeutics; Other, BioAge Labs; Other, GreenLight Biosciences Holdings, PBC.
In numbers
- Trades disclosed
- 144
- Buys
- 28
- Sells
- 3
- Bought
- $314.5M
- Sold
- $4.1M
- Companies
- 19
- Companies where not an officer
- 16
- First trade
- 3 Nov 2016
- Last trade
- 10 Aug 2026
- Last filed
- 10 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill TherapeuticsBiotechnology | SEC FORM 4 Code C | —1,599,993 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill TherapeuticsBiotechnology | SEC FORM 4 Code C | —1,701,541 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill TherapeuticsBiotechnology | SEC FORM 4 Bought | $5.0M312,500 at $16.00 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,599,993 | filing |
| 10 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,701,541 | filing |
| 6 Aug 2026filed 10 Aug 2026 | BLSM BlossomHill Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,904 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code J | —4,528,186 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code J | —2,692,459 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code J | —1,704,862 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code J | —130,865 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code J | —4,528,186 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code J | —2,692,459 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code J | —1,704,862 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | BBOT BridgeBio Oncology TherapeuticsBiotechnology | SEC FORM 4 Code J | —130,865 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,675 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,675 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | HLXC Helix Acquisition Corp. IIIFunds, Shells & SPACs | SEC FORM 4 Code A | $5.0M497,500 at $10.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | HLXC Helix Acquisition Corp. IIIFunds, Shells & SPACs | SEC FORM 4 Bought | $8.0M800,000 at $10.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | HLXC Helix Acquisition Corp. IIIFunds, Shells & SPACs | SEC FORM 4 Code A | $5.0M497,500 at $10.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | HLXC Helix Acquisition Corp. IIIFunds, Shells & SPACs | SEC FORM 4 Bought | $8.0M800,000 at $10.00 | filing |
News
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung CancerBLSM · manilatimes.net · 22 Oct 2026
0 headlines in the last 90 days name Bihua Chen; 1 article from the last 14 days about the 3 companies they traded most, at most three about any one of them.